Immunogenicity Assessment of Peg-filgrastim vs. Neulasta® as Adjunct to Chemotherapy in Patients With Breast Cancer

NCT03511378 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

138

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Lupin's Pegfilgrastim
DRUG: Neulasta®

Sponsor

Lupin Ltd.